Clinical efficacy of mebeverine for persistent nocturnal enuresis after orthotopic W‐neobladder

• Published in: BJU international 2022-03, Vol.129 (3), p.387-393
• Main Authors: Hashem, Abdelwahab, Abdellutif, Mohamed M., Laymon, Mahmoud, Abdullateef, Muhamad, Abdelhamid, Abdalla, Mosbah, Ahmed, Abol‐Enein, Hassan
• Format: Article
• Language: English
• Subjects: Adult; bladder; Bladder cancer; BladderCancer; blcsm; Constipation; continence; Cystectomy; Enuresis; Female; Humans; Incontinence; Male; mebeverine; Nocturnal Enuresis - drug therapy; orthotopic; Patients; Phenethylamines; Placebos; Quality of Life; substitute; Treatment Outcome; Urinary Bladder Neoplasms - surgery; Urinary Reservoirs, Continent; Urology; uroonc
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.15555

Objectives To investigate the efficacy of mebeverine for nocturnal incontinence in male patients with an ileal orthotopic bladder substitute (OBS). Patients and Methods A randomised controlled trial was carried out for adult male patients who were nocturnal incontinent. Patients were allocated to receive mebeverine 200 mg or placebo once a day in the evening for 3 months. The primary outcome was to compare the continence status between groups, assessed by the urinary domain of the Bladder Cancer Index (BCI) and pad usage. The secondary outcomes were to assess the safety of mebeverine. Results There were 55 patients in the placebo group and 58 in mebeverine group who completed the follow‐up. The median (interquartile range) interval between OBS surgery and starting treatment was 9 (4–13) years in the placebo group and 9 (6–13) years in the mebeverine group. The mean (SD) 3‐month urinary domain score of the BCI was 70.8 (5.6) and 86.4 (14.2) in the placebo and mebeverine groups, respectively (P